S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
NYSE:GKOS

Glaukos (GKOS) Stock Price, News & Analysis

$96.50
+1.37 (+1.44%)
(As of 04/19/2024 ET)
Today's Range
$94.16
$98.70
50-Day Range
$84.31
$101.19
52-Week Range
$45.38
$102.33
Volume
697,810 shs
Average Volume
516,267 shs
Market Capitalization
$4.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$99.80

Glaukos MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
3.4% Upside
$99.80 Price Target
Short Interest
Bearish
6.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.75mentions of Glaukos in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$22.91 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.18) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.52 out of 5 stars

Medical Sector

264th out of 911 stocks

Surgical & Medical Instruments Industry

32nd out of 97 stocks

GKOS stock logo

About Glaukos Stock (NYSE:GKOS)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

GKOS Stock Price History

GKOS Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Glaukos (NYSE:GKOS) PT Raised to $100.00
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Glaukos CFO sells over $163k in company stock
Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)
5 Analysts Have This To Say About Glaukos
GKOS Apr 2024 140.000 call
GKOS Apr 2024 92.500 put
GKOS Apr 2024 80.000 put
Glaukos Corp Director Mark Foley Sells 4,560 Shares
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/20/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
907
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$99.80
High Stock Price Target
$120.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+3.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-134,660,000.00
Pretax Margin
-42.49%

Debt

Sales & Book Value

Annual Sales
$314.71 million
Book Value
$9.46 per share

Miscellaneous

Free Float
46,273,000
Market Cap
$4.84 billion
Optionable
Optionable
Beta
1.08
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives


GKOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GKOS shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price target for 2024?

9 brokerages have issued 1-year price targets for Glaukos' stock. Their GKOS share price targets range from $65.00 to $120.00. On average, they expect the company's share price to reach $99.80 in the next year. This suggests a possible upside of 3.4% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2024?

Glaukos' stock was trading at $79.49 on January 1st, 2024. Since then, GKOS shares have increased by 21.4% and is now trading at $96.50.
View the best growth stocks for 2024 here
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GKOS earnings forecast
.

How can I listen to Glaukos' earnings call?

Glaukos will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.07. The medical instruments supplier earned $82.40 million during the quarter, compared to the consensus estimate of $81 million. Glaukos had a negative trailing twelve-month return on equity of 22.67% and a negative net margin of 42.79%. The business's revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.53) earnings per share.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.34%), Taylor Frigon Capital Management LLC (0.10%), State of Alaska Department of Revenue (0.06%), Maryland State Retirement & Pension System (0.04%), SteelPeak Wealth LLC (0.01%) and Caldwell Sutter Capital Inc. (0.00%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GKOS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners